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 T helper (Th) cells are a crucial player in host defense but under certain conditions can 
contribute to the pathogenesis of inflammatory and autoimmune diseases. Beside the Th1/Th2 
subset, several additional Th subsets have been identified, each with a distinctive transcription 
factor, functional properties, signature cytokine profile, and possible role in the pathophysiology 
of diseases. These newer Th subsets include Th17, regulatory Th cells (Tregs), and more 
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recently, Th9, Th22, and follicular T helper cells. Interestingly, imbalance of Th subsets 
contributes to the immunopathology of several disease states. Therefore, targeting the imbalance 
of Th subsets and their signature cytokine profiles by a safe, effective and inexpensive 
nutraceutical agent such as curcumin could be helpful to treat autoimmune and inflammatory 
diseases. In this study different Th subsets and how the imbalance of these subsets could promote 
pathology of several diseases has been reviewed. Furthermore, the role of curcumin in this 
process will be discussed and the impact of targeting Th subsets by curcumin. 
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Introduction  
Immune system mounts an effective and appropriate response towards several pathogens such as 
viruses, bacteria, fungi, parasites, tumors, allergens, and other immune stimulants [1]. T cells, the 
cellular base of cell-mediated immunity (CMI), are the main subtypes of lymphocytes [2]. The 2 




 T [2]. T helper (Th) cells are the 
subpopulations of CD4
+
 T lymphocytes that is crucial in adaptive immune responses [2]. They 
exert distinct biological functions such as recruiting neutrophils, eosinophils, basophils, and mast 
cells to sites of stimulations, inducing macrophages to enhanced anti-microbial activity, helping 
B cells to makes antibodies, and production of chemokines and cytokines for shaping and 
orchestrating of various immune responses [2]. Activated CD4
+ 
Th lymphocytes based on their 
function, transcription factors and signature cytokines are differentiated and classified into 
various distinct subsets such as Th1, Th2, Th9, Th17, Th22, T-regulatory (Tregs), and follicular 
T helper (Tfh) cells [2]. 
 
Undoubtedly, the balance between Th cytokine secretion and their responses are necessary for 
orchestrating the normal immune responses against intracellular and extracellular pathogens, 
tumor cells, tolerance to autoantigens and alteration in Th1-Th2 and Th17-Treg balance results in 
several diseases such as allergic and atopic disease, tumors and autoimmune and inflammatory 
states such as Parkinson’s disease, Alzheimer’s disease, inflammatory bowel disease (IBD),  and 
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rheumatoid arthritis (RA) [2]. Therefore, tending to rebalance Th imbalance may be a therapeutic 
way for manipulating immune responses.  
Nowadays, 25% of current drugs are made from herbal medicine and also 10% of all medications 
are produced from microbial sources [3, 4]. Several herbal medications such as curcumin act as 
an immunomodulator, thus, could be a benefit for changing the immune response [5-8]. 
Curcumin is used since time immemorial as a dietary spice for the management of inflammatory 
conditions [9]. Curcumin has shown various biological and pharmacological actions including 
immunomodulatory, anti-oxidant and anti-inflammatory properties [9]. Based on various in-vitro 
and in-vivo studies curcumin has shown therapeutic potential in several Th cells-mediated 
conditions [9].  
Therefore, here we review the different Th subsets and how the imbalance of these subsets could 
promote the pathology of diseases and the potential role of curcumin in modulating these 
imbalances.  
 
The role of CD4 Th lymphocyte subsets  
CD4
+
 T cells have a central role in defending the body against pathogens, however, they could 
also be pathogenic and driving inflammation. Activated CD4
+
 Th lymphocytes were classified 
into different subsets including Th1, Th2, Th9, Th17, Th22, Tfh and Tregs cells [10-12]. Th1 
cells produce mainly interleukin (IL)-2 and interferon-gamma (IFN-γ).  It also secretes a number 
of cytokines such as granulocyte-macrophage-colony-stimulating factor (GM-CSF), tumor 
necrosis factor-beta (TNF-β) and lymphotoxin as well as various factors which trigger Th1 
differentiation [10-12]. 
IFN-γ-secreting Th1 cells increases toll-like receptors (TLRs) expression [13], promotes class 
switching of immunoglobulin G (IgG) and pathogenic autoantibody production [14], increases 
antigen presentation through major histocompatibility complex (MHC) [15], as well as 
suppression and induction of over 200 genes whose functional significance remains unknown 
[15]. Th1 cells also stimulate the bactericidal activity of phagocytes, activate macrophages, 
increased phagocytosis, and responsible for cell-mediated immunity [15]. IFN-γ, the signature 
cytokine of the Th1 subset, is a potent pro-inflammatory cytokine which plays crucial roles in 
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immunopathology [16]. IFN-γ is associated with the immunopathology of different autoimmune 
states [16]. 
By contrast, Th2 cells subset produce IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-25, and 
Amphiregulin [2]. Th2 cells cause antibody production, eosinophil activation and recruitment, 
and inhibition of various macrophage functions [2, 17]. They also defense host against 
extracellular parasites including helminths as well as involves in the induction and persistence of 
various allergic and atopic diseases [2, 17].  
The dichotomy of the Th1/Th2 cells axis was broken down after the identification of Th17 and 
Tregs cells  [2]. Th17 cells are characterized by expression of the transcription factor retinoid-
related orphan receptor-γt (RORγt) and secrete potent pro-inflammatory cytokines [18]. TGF-β 
and inflammatory cytokines have pivotal roles in the production of Th17 cells [19]. However, 
under certain states, these cells are responsible for the central nervous system (CNS) 
inflammatory demyelination and several inflammatory and autoimmune diseases, including 
asthma and allergy, RA, SLE, MS, IBD and psoriasis. [19]. 
The other subset of CD4
+






, and Forkhead box P3 (FoxP3
+







22]. Treg cells suppress inflammation and autoimmunity by inhibiting immune responses and 
autoreactive effector T cells. A reduction in function and/or frequency of these cells contributes 
to conditions such as enteropathy, polyendocrinopathy, immune-dysregulation and X-linked 
syndrome (IPEX) [23-25]. Treg and Th17 cells are potentially associated with protection, 
pathogenesis, and progression of autoimmunity [26, 27]. Tregs have a protective role in 
autoimmune conditions, whereas Th17 cells enhance the progression of autoimmune diseases  
[26-28]. The Th cells subpopulation balance is critical for modulation of the immune system. 
Targeting the Th cells imbalance by safe and effective nutraceuticals may provide clinical 
efficacy in the conditions such as autoimmune diseases, asthma and allergy, inflammation, and 
organ transplantation. 
An overview of the immunomodulatory properties of curcumin 
Interest in the use of nutraceuticals and phytochemicals are growing nowadays so that 25% of 
current drugs are made from herbal medicines [29, 30]. Curcumin is a polyphenolic compound 
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which first described in 1910 [29, 30]. Multiple studies have demonstrated that curcumin is safe 
and effective in humans [30-34]. Curcumin possesses diverse pharmacological functions such as 
immunomodulatory and anti-inflammatory activities [30-34]. The immunomodulatory activities 
of curcumin which protect against immune-mediated diseases are due to its interaction with 
immune system cells [35-44]. Curcumin also interacts with several transcription factors and 
signal transducers [44, 45]. Curcumin reduces the numbers of neutrophils and eosinophils and 
increases the lymphocyte and NK cells count [35-44]. Curcumin also increases macrophage 
migration and infiltration as well as inhibits the activation of NF-κB [44, 45]. Moreover, 
curcumin reduces M1 macrophage polarization and induces M2 macrophage polarization [44, 
45]. The functional properties and multiple pharmacological activities of curcumin on the 
immune system originate from NF-κB suppression and preventing the nuclear translocation of 
NF-κB p65 subunit [44, 45]. NF-κB has a crucial role in producing proinflammatory cytokines 
[44-46]. Therefore, curcumin and other NF-κB inhibitor agents are able to modulate and 
decreases the production of pro-inflammatory mediators. [45-47]. Curcumin also modulates 
immune responses by modulating IgG, IgM, and sIgA production.  
Therefore, curcumin modulates the immune system by interacting with immune cells and 
potentially might have a therapeutic role in various inflammatory and autoimmune conditions. 
We have reviewed the therapeutic effect of curcumin by restoring the balance between various 
Th subsets. 
Effects of curcumin on Th subset balance 
There is growing evidence that curcumin regulates the function and proliferation of immune cells 
(Fig.1). Investigation of curcumin on modulating the immune response [37] showed that the 
development of CTLs and the proliferation of splenic lymphocytes is significantly reduced by 
curcumin [37]. Curcumin inhibits the activation of NF-kB irreversibly, thereby impairing the 
expression/production of TNF-α and IL-12 by peritoneal macrophages and IFN-γ and IL-2 by 
splenic T lymphocytes [37]. Curcumin significantly reduced IL-12 production by heat-killed 
Listeria monocytogenes (HKL)-stimulated macrophages or lipopolysaccharide (LPS). Curcumin 
administration inhibited IL-12 production by HKL or LPS mediated macrophages stimulation 
which leads to Th1 cytokine profile inhibition [48]. This suggests that curcumin suppresses Th1 
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cytokine production by inhibiting IL-12 production thereby demonstrating its potential in the 
Th1-mediated disease states. 
It is also a powerful inhibitor of T-lymphocytes proliferation (Fig.1). Curcumin inhibited IL-2-
dependent DNA synthesis by mouse CD4
+
 T-lymphocytes, IL-2 and CD25 expression, 





 regulatory T-cells treatment with curcumin down-regulated FoxP3 expression as 
well as Treg cells suppressor function [49]. 
Evidence suggests that curcumin shifts the Th1/Th2 balance towards Th2-type response in 
human peripheral mononuclear cells (PBMCs) [50]. Curcumin supplementation impairs 
Th1/Th17 cells differentiation during encephalomyelitis whilst induces Th2 cells differentiation. 
Feeding with 2% curcumin produced an anti-inflammatory phenotype in DCs [51]. These 
findings demonstrate that curcumin silences Th17/IL-23-mediated immunopathology through 
enhancing STAT-3 interaction in DCs.  
When human CD4
+
 T cells were stimulated with anti-CD2/CD3/CD28 and treated with 
curcumin, it inhibited cell proliferation, differentiation, and cytokine production suppressed 
CD4
+
 T cell activation (Fig.1). In addition, curcumin increased CCR7, L-selectin, and TGF-β 
expression at the late phase of T cell activation. Moreover, TGF-β is involved in curcumin-
mediated late-phase Treg cells generation and the regulation of T cell activation (Fig.1). 
Curcumin trough augmenting CCR7, CD69, TGF-β and L-selectin expression followed by Treg 
cells generation not only blocks but regulates CD4
+





 Treg cells have a pivotal role in regulating the immune responses and critical to the 
maintenance of immunological tolerance to peripheral self-antigens and suppressing deleterious 
immune responses to the host [27], whereas Th17-cells contribute to the development, induction 
and progression of auto-inflammatory disorders [53]. Breaking the balance between Treg cells 
and Th17-cells was favoring the pro-inflammatory Th17 responses and recently implicated in 
several autoimmune diseases [53] raising the possibility of discovering orally available small 
molecules which can modulate the function of Th17 cells or the downstream signaling of the IL-
17 receptor [54]. Therefore, inhibiting the master regulator of Th17 cells, RORγt, is a potential 
therapeutic target for the treatment of inflammatory and autoimmune disorders [54]. The role of 
Th17 cells in the immunopathology of neuroinflammatory disorders such as MS, AD, PD, and 
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schizophrenia has been clarified recently [55]. The expression of the IL-17A and RORγt, a Th17 
cell related cytokine profiles, was significantly reduced in curcumin-treated groups. These 
findings showed that curcumin inhibited the induction, differentiation, development, and 
progression of Th17 cells in Th17-related disorders [56] (Fig.1). 




 Treg cells [57]. According to 
the role of curcumin in modulating Treg cells populations and function, it may be feasible in 
some cases to use curcumin as an immunotherapeutic agent for Treg-mediated diseases, such as 
sepsis and tumors. These results collectively indicate that curcumin is an immunomodulatory and 
immunosuppressive agent which inhibits cell-mediated cytotoxicity (CMC), cell proliferation, 
and pro-inflammatory cytokines production through inhibiting NF-kB activation and its nuclear 
translocation (Fig.1). 
Curcumin on Th balance in autoimmune disease 
Autoimmune diseases are mainly caused by the immunological intolerance to self-antigens [27]. 
Myasthenia gravis (MG) is mainly caused by loss of self-tolerance, which allows the 
development of autoreactive lymphocytes [58]. The exact mechanisms involved in the failure of 
self-tolerance in autoimmune diseases have not been fully elucidated, one possible mechanism is 
deficits in numerical, functional, and migratory properties of Tregs cells [58]. When the safety 
and efficacy of curcumin in experimental autoimmune myasthenia gravis (EAMG) were 
investigated, curcumin administration ameliorated the clinical manifestation of EAMG, down-
regulated the expression of MHC class II and CD80 and CD86 co-stimulatory molecules, 
suppressed the levels of pro-inflammatory cytokines and up-regulated the levels of anti-
inflammatory cytokines  [59]. Curcumin administration shifted the balance of Th1/Th17 toward 
Th2/Treg and promoted the differentiation of B cells into a subset of B10 cells [59]. Therefore, 
curcumin effectively ameliorates the clinical score of EAMG and is a potential management 
option for the treatment of MG. 
IPEX syndrome is an autoimmune disease in boys which is lethal and is caused by mutations in 





 Treg cells [61]. Currently, there are no effective therapies for IPEX  
and immunosuppressive therapy in patients is generally ineffective and causes several side 
effects [60, 61]. Curcumin administration via suppressing the Th1/Th2/Th17 responses in mice 
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attenuated the scurfy-induced immune disorder, a model of IPEX syndrome [62]. Curcumin 
administration reduced all of the Th1/Th2/Th17 cell populations and attenuated clinical 
symptoms of scurfy mice.  
A good animal model for MS is an experimental autoimmune encephalomyelitis (EAE). It is a 
Th1 cell-mediated autoimmune demyelinating disease of the nervous system [63]. IL-12 trough 
inducing Ag-specific Th1 cells has a crucial role in the pathogenesis of CNS demyelination in 
EAE model and MS patients. Curcumin exhibits an inhibitory effect on the generation of pro-
inflammatory cytokines by human macrophages and monocytes ages and has inhibited the 
STAT-4 activation and IL-12 production in the EAE model [44]. Curcumin by reducing the IL-
12 production from macrophage/microglial cells and suppressing the neural Ag-specific Th1 
cells differentiation significantly reduced the clinical severity and duration of EAE [44]. The 
EAE mice express higher levels of IFN-γ, IL-12, IL-17, and IL-23 in the CNS and lymphoid 
organs which significantly decreased following curcumin treatment. Curcumin treatment resulted 
in a decrease in the secretion of IFN-γ, IL-12, IL-17, and IL-23 in-vitro and in-vivo [64] 






 Treg cells populations, 
peroxisome proliferator-activated receptor γ (PPARγ) and  IL-10 expression in the lymphoid and 
CNS organs of EAE mice [64] (Fig.1). The Janus kinase-STAT pathway inhibition by curcumin 
markedly decreased Th1 differentiation and T cell proliferation by inhibition of IL-12 [65-67] 
(Fig.1).  
Effects of nanocurcumin supplementation on Th17 cells frequency, transcription factor 
expression, and Th17-related cytokines expression in healthy controls and patients with 
relapsing-remitting multiple sclerosis (RRMS) and also from patients whose received placebo at 
baseline and after 6 months of treatment were investigated [68]. Results showed that Th17 cells 
population in MS patients when compared with the healthy control group significantly increased. 
The nanocurcumin group showed a significant reduction in Th17 associated parameters such as 
Th17 proportions, RORγt, and IL-17 expression and also IL-17 secretion, but mRNA expression 
and protein levels of IL-23 were not significantly changed. While, in the placebo group, there are 
no significant changes in these parameters. Results imply that the increase in Th17 cells 
proportion might contribute to the pathogenesis of RRMS and nanocurcumin is able to restore 
these Th17 cells dysregulated populations in MS patients [68]. These findings showed that 
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curcumin differentially regulates CD4
+
 T helper cell responses, reduced the duration and clinical 
severity of EAE by inhibiting IL-12 signaling in T cells and suggest its use in the treatment of 
MS and other Th1 and Th17-mediated autoimmune conditions [67-70]. Therefore, curcumin by 
influencing the Th1 and Th17 balance and secretion of pro-inflammatory mediators is a novel 
potential natural therapeutic agent for MS treatment. 
Curcumin as a natural immunosuppressant agent has a bright prospect for preventing 
periodontitis and RA [71]. Periodontitis is a rising public health problem as well as a risk factor 
for the development of RA. It is mainly triggered by Porphyromonas gingivalis [72]. P. 
gingivalis in humans and animal models is able to induce experimental autoimmune arthritis 
through its unique bacterial peptidyl arginine deiminase [73, 74]. Curcumin appears to be an 
effective anti-bacterial agent against P. gingivalis biofilm formation and infection [71]. 
Curcumin also exerts unique immunosuppressant properties through the promotion of Treg cells 
population and inhibition of Th17 pro-inflammatory responses suppressing autoimmunity [71] 
(Fig.1). Results affirmed that curcumin as a natural product is a potent protective compound for 
the management of both periodontitis and also RA. 
Curcumin has been shown to ameliorate various nicotine-induced chronic inflammatory 
disorders [75]. The cytokines profile of Th1 and Th2, mRNA and protein expression of 
cytokines, transcription factors (AP-1), regulatory molecule (P53), growth factors (GM-CSF; 
TGF-β) in female Wister rats were determined to understand the mechanisms of curcumin action 
in this area. Data showed that the nicotine through up-regulation and down-regulation of 
different factors induces Th1/Th2 balance disruption. The study demonstrated that this Th1/Th2 
imbalance was safely and effectively restored by curcumin administration [76].  
The Th subsets imbalance is implicated in the pathogenesis of SLE [12]. Curcumin was added 
after stimulating CD4
+
 T cells from untreated SLE patients and healthy volunteers with Th17 
differentiating factors. After curcumin administration Th17 percentages decreased, IL-17A 
productions reduced, Treg cells populations and subsequently TGF-β1 productions increased. 
These findings were not observed in CD4
+ 
T cells cultures of individuals without SLE [77]. This 
shows that curcumin could rebalance Th17/Treg imbalance of SLE patients. 
Effects of curcumin on Th subset balance in psoriasis 
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Psoriasis is an inflammatory disease of the skin which is characterized by keratinocytes hyper-
proliferation and leukocytes infiltration [78, 79]. Recent evidence showed that several cytokines 
are involved in their pathogenesis [78-81]. It was suggested that the IL-17A/IL-23 cytokine axis 
have an important role in the pathophysiology of psoriasis [80, 81]. Curcumin besides its anti-
bacterial and antioxidant activity is also able to decrease the expression of pro-inflammatory 
cytokines in keratinocytes [82-84]. Results showed that the curcumin gel formulation when used 
topically effectively suppressed imiquimod (IMQ), -induced psoriasis-like inflammation[83, 84]. 
In addition, curcumin by inhibiting IL-1β/IL-6 production indirectly down-regulated IL-17A and 
IL-23 expression [83, 84]. Thus, curcumin is able to ameliorate inflammation induced in the 
IMQ-induced psoriasis-like mice model by directly down-regulating pro-inflammatory cytokines 
production. 
Effects of curcumin on Th1/Th2 and Th17/Treg balance in IBD 
IBD is a disease of the gastrointestinal tract which mainly divided into two major subgroups: 
Ulcerative Colitis and Crohn’s disease [85, 86]. Ulcerative colitis is an inflammatory disorder of 
the mucosa of the colon that affects millions of people worldwide and impairs their quality of 
life. While the etiology of IBD is not completely determined, it appears to be induced by pro-
inflammatory cytokines such as TNF-α [85, 86]. Emerging evidence shows intriguing 
pharmacological effects of curcumin [44, 45, 47]. These include inhibitory effects on inducible 
nitric oxide synthase (iNOS), Cyclo-oxygenase (COX)-1 and-2, lipoxygenase (LOX), TNF-α, 
IFN-γ, and the NF-kB [44]. NF-kB is an essential factor for up-regulation of pro-inflammatory 
cytokines that increase in inflammatory diseases [44]. Recently, the safety and therapeutic effects 
of curcumin have been evaluated in various experimental models of IBD [44]. Curcumin changes 
the cytokine profiles of Th1 cells toward the anti-inflammatory Th2 type [87]. The safety profile 
and inhibitory effects of curcumin on major pro-inflammatory mediators suggest that it has a 
promising future for the treatment of patients with IBD [87]. Mitogen-activated protein kinases 
(MAPKs) and the c-Jun N-terminal kinase (JNK) modulate the transcription and expression of 
several genes that are involved in the inflammatory process of various chronic inflammatory 
diseases such as ulcerative colitis [85, 86]. Trinitrobenzene sulphonic acid (TNBS)-induced 
colitis, an animal model of IBD, has been described as Th1-mediated inflammation. The TNBS-
induced colonic injury was also characterized by an increase of the TNF-α and reduction of the 
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IL-10. Curcumin decreased the expression of Th1-related cytokines and increased the expression 
of Th2-related cytokines in the mucosa of the colon [88]. Curcumin exerted therapeutic effects 
on colitis by modulating the Th1/Th2 balance and regulating the shift from Th1 to Th2 responses 
in TNBS-induced colitis [88]. Curcumin reduced the p38 MAPK activation and decreased COX-
2 and iNOS expression. Also, the levels of TNF-α were significantly decreased and the IL-10 
production was significantly increased in curcumin-treated rats [89, 90]. CD4
+
  T lymphocytes 
proliferation was induced and secretion of Th2-related cytokines such as IL-4 and IL-5 were 
significantly increased by ConA and reduced by curcumin [91] (Fig.1).  






 Treg cells, while the secretion of 
TNF-α, IL-2, IL-6, IL-12 p40, IL-17 and IL-21 and the expression of co-stimulatory molecules 
such as TLR4, CD54, CD205, CD252, CD254, and CD256 on DCs were significantly decreased 
(Fig.1). Curcumin potentially suppresses DCs maturation, induce tolerogenic option, and 
modulates DCs activation to enhance the inhibitory functions of Treg cells in colonic mucosa of 







Treg cells expansion in the colonic mucosa of experimental colitis [93]. In conclusion, the 
inhibition of NF-κB expression and p38MAPK signaling by curcumin could explain the reduced 
COX-2, iNOS, and inflammatory cytokines (TNF-α, IL-2, IL-6, IL-12 p40, IL-17 and IL-21) 
expression in colonic mucosa and reducing the development of chronic experimental colitis. 
Therefore, in animal models of IBD and in humans, curcumin has demonstrated therapeutic 
potential.  
Effects of curcumin on Th1/Th2 and Th17/Treg balance in asthma and allergy 
Asthma and allergy worldwide increased particularly in industrially developed countries over the 
last few decades. Thus, recent progress has been made to explore novel alternative therapies 
includes herbal medicines. Curcumin has traditionally been used and recently has been shown to 
be effective in a treat and ameliorating inflammatory and immune-mediated disorders such as 
fever, pain, asthma, bronchitis, arthritis, dermatitis, and allergic inflammation [94]. A murine 
model of latex allergy showed an increase in the Th2 type of immune responses [95]. Latex-
sensitized mice showed an increased in serum IgE, latex specific IgG1, IL-4, IL-5, IL-13, 
eosinophils count, and lungs inflammation [95]. Treatment of Latex-sensitized mice with 
curcumin showed a significant reduces in Th2-related responses with a simultaneous reduction in 
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eosinophils count. Inflammation of lung in curcumin-treated mice was markedly reduced and 
expression of co-stimulatory molecules on macrophages and DCs were significantly decreased 
[95]. Further, the anti-asthmatic properties of curcumin, through the intranasal route in an 
ovalbumin (OVA)-challenged asthma mouse model has been evaluated. Exposure to LPS by 
increasing IgE level, Th2-related cytokine IL-4, and IL-5 expression, and histamine release, 
exacerbates airway inflammation. administration of curcumin through the intranasal route 
reduced airway inflammation and exacerbation, whereas dexamethasone, was not as good as 
curcumin [96].  
The effect of curcumin on the lymphocytes of atopic asthmatic patients was investigated. 
Lymphocytes stimulated with Dermatophagoides farinea in the absence or presence of curcumin. 
The protein levels of IL-4, IL-5, and GM-CSF in the culture supernatants were determined. 
Curcumin inhibited Dermatophagoides farinea-induced lymphocyte proliferation and IL-2 
production (Fig.1). IL-2 administration in the presence of curcumin restored the proliferative 
capacity of lymphocytes to Dermatophagoides farinea. Moreover, curcumin in a dose-dependent 
manner inhibited IL-4, IL-5, and GM-CSF production [97].  
The protective effects of curcumin on food allergies in OVA and alum immunized mice were 
investigated. Results showed that curcumin significantly attenuated increased levels of IgE, 
IgG1, and MCP-1 in OVA-immunized mice. Furthermore, curcumin as an anti-allergic agent 
showed an immunosuppressive and immunoregulatory effect through modulating Th1/Th2 
balance [98]. Also, curcumin strongly suppressed Th17 cells expansion and increased Treg cells 
populations (Fig.1). Curcumin substantially decreased IL-17A level and increased IL-10 level, 
blocked OVA-induced increases in eosinophils and significantly rebalanced Treg/Th17 
imbalance in bronchoalveolar lavage fluid and in the lung [99]. Curcumin administration 
significantly attenuated the inflammatory conditions in the asthma model by regulating 
Treg/Th17 balance [99]. These results suggest that curcumin administration as a therapeutic drug 
may be useful for controlling amelioration of Th2-mediated allergic diseases. 
Effects of curcumin on Th1/Th2 and Th17/Treg balance in organ transplantation  
DCs and Treg cells are essential factors in the development of organ transplant tolerance. 







 Tregs cells populations and suppressive functions in-vitro and in-
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vivo [100] (Table.1. and .2). Curcumin-treated DCs demonstrated a significant reduction in co-
stimulatory molecules expressions. Curcumin-treated DCs also decreased their IL-12 mRNA 
expression and protein secretion. Functionally, the allostimulatory capacity of DCs and 
intracellular IFN-γ expression in response to T cells stimulation significantly decreased. Hypo-









cells phenotype that put on suppressive effects on naïve CD4
+ 
T cells, although the effect was not 







 Tregs and reduced subsequent alloproliferative capacity in mice [100].  
The effect of curcumin in the prevention or progression of acute graft-versus-host disease 
(GVHD) in a murine model were investigated [101] (Table.1. and .2). When treated with 
curcumin the acute GVHD mice showed a reduction in the severity of acute GVHD. While flow 







 Tregs cells populations, as well as the CD8+ Treg cells, were notably 
increased [101]. Therefore, these results collectively revealed that curcumin by up-regulation of 
Treg populations percentage and functions has protective effects on acute GVHD. 
Curcumin on Th1/Th2 and Th17/Treg balance in cancers   
Tumor cells escaping from the immune system are mostly targeted and inhibited by effector and 
memory T cells function [102-104]. Curcumin, by targeting several molecular molecules and 
transcription factors, has shown great antitumor activity. Several pieces of evidence have shown 
the immune-protective potential of this natural polyphenol against tumor cells [105, 106]. Effect 
of curcumin on prevention of tumor-induced immune dysfunction was examined and results 
showed that in tumor-bearing hosts, curcumin inhibited loss of T-cell populations, expanded 
central and effector memory T cell percentage, reversed the Th2-related immune responses and 
prevented T-cell proliferation inhibition [107]. Moreover, tumors up-regulated Treg cell 
populations and induce the production of the immunosuppressive cytokines such as TGF-β and 
IL-10 [108]. Curcumin also enhances CD8
+
 T cells cytotoxicity against tumors by changes in the 
tumor microenvironment. Moreover, results showed that the accumulation and function of T-
cells were increased through the inhibition of different immunosuppressors agents [109]. In 
patients with colon cancer after curcumin therapy, there was a suppression of the FoxP3 gene 
expression showing a reversal of bounding of FoxP3 to T-bet which prevented IFN-γ expression 
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[110]. Collectively, in contrast to other conditions which curcumin increased Treg cells 
population and suppressed Th1 responses, in cancer microenvironment, curcumin treatment 
convert Tregs to Th1 cells by increasing IFN-γ production and suppressing FoxP3 expression. 
Due to the various properties of curcumin in cancer, asthma, allergy, transplantation, and 
autoimmune disease, understanding the mechanisms of action of curcumin is an intriguing 
challenge. Collectively, these findings indicate that curcumin could be exploited for the 
prevention and management of tumor-induced immune system suppression and may have the 
potential for clinical application. 
Conclusion and future perspectives  
In brief, curcumin has potent immunosuppressive properties both in vitro and in-vivo. Curcumin 
has the potency to selectively enhance the function and number Tregs as well as suppress 
macrophage and DC-mediated differentiation of Th1 and Th17. The effects of curcumin on Th9 
and Th22 are unclear and need further investigations. Emerging evidence points towards 
curcumin having a therapeutic potential in Th1-, Th2- and Th17-driven inflammatory as well as 
autoimmune diseases. However, confirmatory clinical data from randomized controlled trials 
would be integral to introduce curcumin to the armamentarium of drugs for these diseases.  
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Table 1. In-vitro studies that have evaluated the effects of curcumin on Th balance.   
Cell lines  
Curcumin 
dose 
Duration Effects  Reference 







Down-regulated the levels of pro-inflammatory 
cytokines (IL-17, IFN- α and TNF- α) and up-






















4 & 24 
hrs 
Resveratrol suppressed NF-κB-regulated gene 
products involved in inflammation (cyclooxygenase-
2, matrix metalloproteinase (MMP)-3, MMP-9, 
vascular endothelial growth factor), inhibited 
apoptosis (Bcl-2, Bcl-xL, and TNF-α receptor-
associated factor 1) and prevented activation of 
caspase-3. IL-1β-induced NF-κB activation 
[2] 
T cell 2.5, 5 and 10 
µm 
0 to 4 
days 
Regulation of T helper 1 (Th1) and Treg [3] 
Raw264.7 cells 200 mg/kg  Inhibition of NF-kb activation in the asthmatic lung 
tissue 
[4] 




Decreased all of the Th1/Th2/Th17 cell populations [5] 
Intestinal epithelial 
cells 
(0–150 mm) 45 min Inhibited IL-1b-mediated ICAM-1 and IL-8 gene 
expression in IEC-6, HT-29, and Caco-2 cells. 
Cytokine-induced NF-kb DNA binding activity 
[6] 
T-lymphocyte 5, 10 and 20 
µm 
120 h Inhibits IL-2 signaling by reducing available IL-2 







1, 10, 30 or 
50 mm 






1.5 and 13.6 
mm 
 Modulates the expression profile of Th1 cells [9] 
T cells 0, 5, 10 and 
20 µm  
0 to 6 
hours 
Expression of the anti-apoptotic protein Bcl-2. [10] 
T cells 0, 2.5, 5, 10, 
and 25 
µg/ml 
30 min Induced a dose-dependent decrease in JAK and 
STAT phosphorylation 
[11] 
Lymphocytes Cr, 10 PM 3 days Curcumin inhibited IL-5, GM-CSF, and IL-4 





0.5m 5 m 1 
and 10 µm 
24 hrs The inhibitory effect on the production of IL-8, MIP-
1a, MCP-1, IL-1b, and TNF-a by PMA- or LPS-
stimulated monocytes and alveolar macrophages 
[13] 
γδ T cells 1 µm 10 µm 




Inhibited isopentenyl pyrophosphate-induced release 
of the chemokines macrophage inflammatory 
protein- 1α and -1β and RANTES. Curcumin also 
blocked isopentenyl pyrophosphate-induced 
activation of NF-kb and AP-1. 
[14] 
Neutrophilic 25, 50 and 
75 µm 
6 hrs Curcumin was found to inhibit LPS-induced cytokine 
production, includingmip-1α, MIP-1β, IL-6, IL-8 
(CXCL-8) and GRO-α. 
[15] 




Curcumin was a potent inhibitor of STAT3 
phosphorylation, and this plays a role in the 
suppression of MM proliferation 
[16] 
Human mantle cell 
lymphoma 
10, 25, 50 
and 100 µm 
8 hrs. Downregulated constitutive active NF-kb and 
inhibited the constitutively active IkB kinase (IKK), 
and phosphorylation of IkB and p65. Curcumin also 
[17] 
ACCEPTED MANUSCRIPT












inhibited constitutive activation of Akt, needed for 
IKK activation. 
Dendritic cells 0, 1, 5 10 
and 25 µm 
45 min Induction of Th1 responses and a normal cell-
mediated immune response. 
[18] 
SUIT-2 0 µm, 10 
µm, 50 µm, 
and 100 µm 
2 hrs IL-8 was inhibited 
NF-kb activity was reduced 
[19] 
EAC cell lines, 
OE33, and OE19 
50mm nano-
curcumin 
48 hrs Decreased the secretion of pro-inflammatory 
cytokines from in vitro activated T cells 
[20] 
CD4+ T cells 0.5, 1.0, 2.5, 
5.0 mg 
48 hrs Inhibition of IL-12 production by macrophages 
stimulated in vitro with either LPS or HKL, leading 
to the inhibition of Th1 cytokine profile (decreased 
IFN-γ and increased IL-4 production) in CD4+ T 
cells. These findings suggest that curcumin may 
inhibit Th1 cytokine profile in CD4+ T cells by 
suppressing IL-12 
[21] 
T cells 20 µg 18 hrs Decreases IL-12-induced STAT4 phosphorylation, 
IFN-γ production, and IL-12 Rβ1 and β2 expressions. 
[22] 
CD 4+ monocytes 20μm or 
30μm 
 Cytokine and chemokine expression and reducing 
both migration and endocytosis 
[23] 
CD8 cytotoxic T 
lymphocytes 
Mice 
10 mm 24 hrs Inhibited the suppressive activity of Treg cells by 
downregulating the production of TGF-b and IL-10 




5–20 mm 48 hours Curcumin selectively induces apoptosis in 
association with the downregulation of STAT-3 and 





With dose of 
0.01 0.1, 1, 5 
& 10 µm for 
48 hours 
48 hrs. Shift the Th1–Th2-type immune balance towards 
Th2-type immunity 
[26] 
BV2 cell line 5 and 10 µm  Inhibited the phosphorylation of STAT1 and 3 as 
well as JAK1 and 2 in microglia activated with 








Reduced p38 MAPK activation in curcumin-treated 
mucosal biopsies enhanced IL-10 and reduced IL-1b. 
We demonstrate dose-dependent suppression of 
MMP-3 in CMF with curcumin. 
[28] 
T cell 2.5, 5 & 10 
 m 




1, 25, 50 µm 12 hr 
[30]s. 
Inhibited the production of pro-inflammatory 
cytokine IL-18 in E. Coli LPS stimulated murine 
macrophage-like cells RAW264.7 
[30, 31] 
Carcinoma cell 







0.1, 1, 10 
and 100 µm 
 Curcumin (diferuloylmethane), NF-κB inhibitor [32] 
Murine spleen 
lymphocytes 
0, 3. 125, 6. 
25, 12.5, 25, 
50, 100, 
200/µmol/L 
24 hrs Suppress the expression of NF~B p65 [33] 
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Human monocytes 1.5-12.5μm 72 hrs Suppressed NF-κB binding and cytokine 






8 hrs Interleukin-2 (IL-2) or alloantigen-induced 
proliferation of splenic lymphocytes, and 





1–100μm 1 hrs Inhibition of NF-κB nuclear translocation as well as 
the induction of downstream inflammatory mediators 
including pro-inflammatory cytokine mrna and 










Inhibited lipopolysaccharide (LPS)-induced 
production of TNF and IL-l by a human monocytic 





20 µm 24 hrs Inhibited the expression of TNF-α-induced IL-1ß, IL-
6, and TNF-α, but not IL-8, in TNF-α-treated 
HACAT cells as well as the TNF-α-induced cyclin E 
expression. In addition, curcumin inhibited the 
activation of MAPKS (JNK, p38 MAPK, and ERK) 
and NF-κB in TNF-α-treated HACAT cells. 
[38] 
Dendritic cells 25 µm 24 hrs Reduced IL-6 and IL-23 [39] 
CD4+ T cell 
cultures of SLE 
patients 
0.1 and 1 
μg/ml 
72 hrs Reduce IL-17A [40] 
Dendritic cells 25 mm  Development of foxp3+ Tregs and reduced 
subsequent alloproliferative capacity 
[41] 
Dendritic cells 10 or 50 mm 24 hrs Curcumin-treated DC induced differentiation of 
native CD41 T cells into Treg resembling Treg in the 
intestine, including both CD41CD251 Foxp31 Treg 
and IL-10- producing Tr1 cells. Such Treg induction 
required IL-10, TGF-b and retinoic acid produced by 
curcumin-modulated DC. 
[42] 
Human CD4+ T 
cells 
0.2 or 2 
mg/ml of 
Curcumin 
3 days Curcumin not merely blocks, but regulates 
CD2/CD3/CD28-initiated CD4+ T cell activation by 
augmenting CD69, CCR7, L-selectin and TGF-b1 




5, 10, 20 μM 36 hours Suppress IL-2 production 
Foxp3 expression was also reduced 
On Tregs after curcumin stimulation 
[44] 
T-cell 60 mmol/L 
 
24 hrs CD8 
T-cell activation was significantly 
Increased when cocultured with curcumin-pretreated 
[45] 
 
Table 2.  In vivo and clinical studies that have evaluated the effects of curcumin on Th balance. 
Animal Curcumin dose Duration Route  Th1 Th2 Th17 Treg Reference 
Rat  (30 mg·kg-1·d-1, 
ip) for 15 days 
15 days i.p Decreased the expression of Th1 cytokines 
increase the expression of Th1 cytokines 
(46) 
Rat  200 mg/kg 2, 4 & 6 
hrs 
i.p Increase in messenger RNA levels and 
protein content of tumor necrosis factor-α, 
(47) 
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interleukin-6, and matrix metalloproteinase-
9 
Rat 50 mg/kg (low-




45 days  i.p  Lowering circulating TNF-α concentration (48) 
Mouse 300 μg curcumin 
(Sigma) in 1% 
carboxymethyl 
cellulose 
 oral Inhibited the phosphorylation of the p65 
subunit of NF-κB in BMMCs 
(49) 
Rat  50 or 100 µg days 0 to 
25 
 Inhibits EAE by blocking IL-12 signaling in 
T cells and suggest its use in the treatment 
of MS and other Th1 cell-mediated 
inflammatory diseases 
(50) 
Mouse  Curcumin gel 
(curcumin 1 g, 
HPC 3 g, azone 1 
g, ethanol (96%) 
17 g, and distilled 
water q.s. to 100 
g. 
10 days  Was capable of impacting the IL-23/IL-17A 
axis by inhibiting IL-1b/IL-6 and then 





Diet   Curcumin demonstrates limited 
effectiveness on Th-1 mediated colitis in IL-
10-/- mice, 
(52) 
Rat  100 mg/kg 6 days intragastric Reduce serum TNF-α and IL-6 levels (53) 
Rat  80 mg/kg body 
weight/day 
21 days oral Th1/Th2 balance through upregulation and 
downregulation of different factors 
(54) 
Rat  30 mg 15 days i.p Increased proportion of IFN-γ/IL-4 in 
splenocytes and circulation. Dex and 
Cur+Dex decreased the expression of Th1 
cytokines but could not increase the 
expression of Th2 cytokines and the 
proportion of IFN-γ/IL-4. Cur exerted 
therapeutic effects on colitis by regulating 
the shift from Th1 to Th2 
(46) 
Mouse curcumin gel 12 days  Relieving TPA-induced inflammation by 
directly down-regulating IFNγ production 
(55) 
Human  10 µm 30 days  After the curcumin therapy, the Forkhead 
box protein (Foxp) 3 positive Treg 
frequency was markedly reduced, the 
frequency of Th1 cells was significantly 
increased in Cca patients. 
(30) 
Rat  50–100 
mg/kg/day 
2 week Oral  Curcumin significantly attenuated the 
damage and caused substantial reductions of 
the rise in MPO activity and tumor necrosis 
factor alpha (TNF)-α. Also, curcumin was 
able to reduce nitrites colonic levels and 
induced downregulation of COX-2 and 
iNOS expression, and a reduction in the 
activation of p38 MAPK; 
(56) 
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Mouse 50, 100 and 300 
mg/kg 
10 days  Curcumin also reduced the levels of nitric 
oxide (NO) and O2-associated with the 
favorable expression of Th1 and Th2 
cytokines and inducible NO synthase. These 
findings suggest that curcumin or 
diferuloylmethane, a major component of 
the food flavor turmeric, exerts beneficial 
effects in experimental colitis and may, 
therefore, be useful in the treatment of IBD. 
(57) 




 The inhibitory effects of curcumin on major 
inflammatory mechanisms like COX-2, 
LOX, TNF-α, IFN-γ, NF-kB and its 
unrivaled safety profile suggest that it has 
bright prospects in the treatment of IBD 
(58) 
Rat  20 mg 20 days i.p  downregulation of Th1 cytokine response 
and NO production by macrophages, and 
their upregulation in NK cells 
(59) 
Rat  1% Cur or 0.02% 2 week diet suppressed (P , 0.05) NF-kB p65 nuclear 
translocation in activated CD41 T-cells. 
(60) 
Muse  10 mM; 100 
μl/mouse 
28 days IP up-regulated activities of the antioxidant 
enzymes, and suppressed serum levels of 
TNF-α and IL-1β. 
(61) 
Mouse 250 µg  intragastric suppression of Th2 responses as evidenced 
by reduced IL-4 and IL-13 production and 
depletion of eosinophils in the lungs, and 
attenuation of lung inflammation through 
expression of molecules such as TSLP, 
MMP-9, and OAT. 
(62) 
Mouse 5 and 10 mg/kg 9th to 
14th day 
i.n Th2 cytokine, IL-5 is responsible for 
eosinophil and neutrophil recruitments to 







2 % 7 days diet Secretion of IL-4 and IL-5 by CD4+ 
lymphocytes of BALB/c mice but not SJL/J 
mice was significantly augmented 
(64) 
Mice 3 mg/ kg or 30 
mg/kg 
16 days oral maintaining Th1/Th2 balance (65) 
Rat  (50–100 
mg/kg/day) 
2 week Oral 
gavage 
downregulation of COX-2 and iNOS 
expression, and a reduction in the activation 
of p38 MAPK 
(56) 
Mouse (50 mg/kg, 100 
mg/kg, 200 
mg/kg). 
28 days ip Th17 cells and significantly increased Treg 
cells. 
(66) 
Mouse 100 μg 14 days  IL-12 and IL-23 that decreased after 
treatment with curcumin. 
(67) 
Mouse 2% 22 days diet enhanced STAT3 phosphorylation and 
suppressed expression of Il12b and Il23a. 
(68) 
Mouse 1% 18 and 
32 week 
age 
diet decreased the proteinuria level and serum 
levels of IgG1, IgG2a and anti-dsDNA IgG 
antibodies in NZB/W F1 female mice 
(69) 
Rat  40 mg/kg 7 days gavage Curcumin pretreatment significantly 
inhibited the expression of IL-1β, IL-2, and 
(70) 
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Mouse 7mg/mL 5 days ip CD8 T-cell activation was significantly 





7 days  suppressed mucosal mRNA expression of 
TNF-α, IL-1β, IL-6, CXCL1 and CXCL2 in 
colonic epithelial tissues. 
(71) 
 
Figure 1. Effect of curcumin on T helper cells differentiation, survival, proliferation, 
polarization, and functions. Curcumin has potent immunosuppressive and immunomodulatory 
effects on T helper cells in-vitro and in-vivo. Curcumin has the potency to selectively enhance 
Tregs percentage and function and suppress macrophages and DCs maturation-mediated Th1 and 
Th17 differentiation. Therefore, curcumin may be an effective therapeutic agent for Th1-, Th2-, 
and Th17-driven inflammatory and autoimmune diseases and its use may thus be useful as a 
good strategy to treat inflammatory and autoimmune diseases. The effects of curcumin on Th9 
and Th22 in unclear and need investigations. 
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